The FDA this week approved the first generic version of Indivior‘s (LON:INDV) billion-dollar opioid addiction treatment, Suboxone.
The generic buprenorphine and naloxone sublingual film, sold by Dr. Reddy’s Laboratories (NYSE:RDY) and Mylan (NSDQ:MYL), is designed to suppress withdrawal symptoms that crop in people addicted to opioids, as well as block the neurochemical effects of opioids.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA approves first generic sublingual film to treat opioid addiction appeared first on MassDevice. (Source: Mass Device)
FDA approves first generic sublingual film to treat opioid addiction
Previous post: FDA Approves First Generic Versions of Suboxone Sublingual Film, Which May Increase Access to Treatment for Opioid Dependence
Next post: FDA approves first generic Suboxone
